207 related articles for article (PubMed ID: 22970245)
1. MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1.
Kim KT; Carroll AP; Mashkani B; Cairns MJ; Small D; Scott RJ
PLoS One; 2012; 7(9):e44546. PubMed ID: 22970245
[TBL] [Abstract][Full Text] [Related]
2. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival.
Kim KT; Baird K; Ahn JY; Meltzer P; Lilly M; Levis M; Small D
Blood; 2005 Feb; 105(4):1759-67. PubMed ID: 15498859
[TBL] [Abstract][Full Text] [Related]
3. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
Mizuki M; Schwable J; Steur C; Choudhary C; Agrawal S; Sargin B; Steffen B; Matsumura I; Kanakura Y; Böhmer FD; Müller-Tidow C; Berdel WE; Serve H
Blood; 2003 Apr; 101(8):3164-73. PubMed ID: 12468433
[TBL] [Abstract][Full Text] [Related]
4. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
6. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
[TBL] [Abstract][Full Text] [Related]
7. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
9. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
[TBL] [Abstract][Full Text] [Related]
10. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
11. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
[TBL] [Abstract][Full Text] [Related]
12. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
13. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
[TBL] [Abstract][Full Text] [Related]
14. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
15. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
16. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
17. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
[TBL] [Abstract][Full Text] [Related]
18. STAT5-dependent regulation of CDC25A by miR-16 controls proliferation and differentiation in FLT3-ITD acute myeloid leukemia.
Sueur G; Boutet A; Gotanègre M; Mansat-De Mas V; Besson A; Manenti S; Bertoli S
Sci Rep; 2020 Feb; 10(1):1906. PubMed ID: 32024878
[TBL] [Abstract][Full Text] [Related]
19. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
20. miR-155 regulative network in FLT3 mutated acute myeloid leukemia.
Salemi D; Cammarata G; Agueli C; Augugliaro L; Corrado C; Bica MG; Raimondo S; Marfia A; Randazzo V; Dragotto P; Di Raimondo F; Alessandro R; Fabbiano F; Santoro A
Leuk Res; 2015 Aug; 39(8):883-96. PubMed ID: 26055960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
